In this study, we aim to investigate a cohort of OSCC patients to (i) determine the prognostic value of T cell-specific markers (CD3, CD4, CD8, and FOXP3) by scoring them using categorical variables, and (ii) determine whether the inclusion of T cell-specific markers (CD3, CD4, and CD8) would identify early-stage OSCC patients with a high risk of tumor recurrence and treatment failure. The gene discussed is CD8A; the disease is neoplasm.